Medications for Addiction Treatment (MAT) Resources
When two disorders or illnesses occur in the same person, simultaneously or sequentially, they are described as comorbid.
Comorbidity also implies that the illnesses interact, affecting the course and prognosis of both.1,2 This research report provides information on the state of the science in the comorbidity of substance use disorders with mental illness and physical health conditions.
Registries are important population health tools that allow organizations to collect, organize, aggregate, and utilize the information for a variety of purposes. Maintaining registries for certain disease states such as depression or diabetes provides easy access to results, identification of care gaps, and level of improvement and can lead to adjustments in care as needed. This Short Take video provides an introduction to registries and how to use them.
An online resource to provide broad access to resources to clarify best practices to support and improve the care for substance-exposed mothers and newborns. The toolkit includes resources to support screening, assessment, and level of care determination; treatment; transitions of care; and education.
The California Department of Health Care Services (DHCS) has implemented the California Medications for Addiction Treatment (MAT) Expansion Project to address the opioid epidemic throughout the state. This website serves as a separate yet complementary resource to the DHCS MAT Expansion Website and provides resources and information related to the four MAT Expansion Project initiatives operated by Health Management Associates.
The California MAT Expansion Project aims to increase access to MAT, reduce unmet treatment need, and reduce opioid overdose-related deaths through the provision of prevention, treatment, and recovery activities. The project focuses on individuals experiencing homelessness, youth, rural, and tribal populations with limited MAT access. The California MAT Expansion Project, composed of nearly 30 initiatives, is funded by grants from the Substance Abuse and Mental Health Services Administration (SAMHSA).
HMAedu.com is an educational resource specifically designed for training treatment teams about addiction, pain, and behavioral health. With over 25 hours of education through the lens of patient-centered care, users can explore topics of interest or follow the suggested curriculum path. Once a user signs in, the learning management system automatically loads modules that are pertinent to the user’s level of training. This automation allows for consistency in messaging to all providers without delivering information beyond the scope of practice. Each course starts with a TED Talks-style overview that is followed by patient-focused modules of 3-10 minutes each. Each module is traced for completion and can be reported back to the client and individual for tracking purposes.
This brief video introduces the concept of brief interventions and review motivational interviewing and mindfulness. Presented by Dr. Lori Raney, Principal, Health Management Associates.
People with substance use disorders are at particular risk for overdoses and developing one or more primary conditions or chronic diseases. During this webinar, presenters will discuss harm reduction as a public health approach that aims to reduce harms related to substance use. Presenters will discuss strategies, policies, programs, and practices that aim to minimize negative health, social and legal impacts associated with drug use, drug policies, and drug laws.
This document consists of common questions and concerns about Medication Assisted Treatment for Ambivalent patients. This document can be used as a starting point to have conversations with your patients. In the end, the patient will be able to make an informed decision that’s in line with their values and hopes for recovery.
This question and answer document answers common questions and concerns that family members have about Medication Assisted Treatment (MAT). The purpose of this document is to assist providers in educating family members.
This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment.
The Medication-Assisted Treatment Of Opioid Use Disorder pocket guide to provide guidance on how to assess the need for treatment, referring to higher levels of care if necessary and the approved frequency and route of administration for treatment of Opioid Use Disorder. In addition, a tool has been provided to determine clinical opiate withdrawal.
Understanding the brain chemistry associated with opioid use disorder treatment is essential: Medications for Addiction Treatment (MAT) restores depleted dopamine in the brain so people impacted by OUD can regain functioning. Recognizing this, therapy and support services for OUD are most effective when provided in accordance with a person's healing process and readiness to engage in treatment.
This module offers a 25-minute video of the neuroscience of addiction as a chronic brain disease presented by HMA’s Corey Waller, MD, MS, FACEP, DFASAM, with emphasis on Opioid Use Disorder (OUD).
"This lecture was developed for audiences of all backgrounds to absorb. From patients to nonspecialist docs. The intent was to move people past the preconceived notion that addiction is a moral failing or choice, to the reality that it is a chronic brain disease that creates maladaptive connections in large swaths of the brain. Over the hundreds of lectures, I have given in my career, I have come to realize that running through 30+ articles in a 70 slide PPT does not move people emotionally. But a good story will. The lecture has coalesced into a story form that is much more compelling than digging through the dense science of voxel dysmorphology, BOLD fMRI technology, and all of the structures postulated to drive craving. If I need a custody officer to "get it" or an administrator to understand the concept, I cannot give them the same lecture I would give a psychiatrist, addiction psychologist, addiction doc, or a neurologist."
Deeper dive on the operational practicalities of delivering MAT and other SUD treatment to clients through telehealth and other remote means; risk and management of relapse and overdose; current expectations regarding privacy rules, documentation, and new regulations from the DEA.
Integrated Care DC is managed by the DC Department of Health Care Finance (DHCF) in partnership with the DC Department of Behavioral Health (DBH). This project is supported by the U.S. Department of Health and Human Services (HHS). A total of $3,500,365, or 81 percent, of the project is financed with federal funds, and $810,022, or 19 percent, is funded by non-federal sources. The contents are those of the author(s) and do not necessarily represent the official views of, or an endorsement by, HHS or the U.S. Government.